Anti-synthetic syndrome with pulmonary arterial hypertension is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical manifestations are complex and often involve multi-system complications. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic-oriented, immune-regulatory therapies and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of pulmonary arterial hypertension associated with anti-synthesis syndrome. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1. Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2.
Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3. Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.